Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-02-01
1997-07-01
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514252, 514253, 514255, 544 96, 544285, 544286, 544295, 544366, 544367, 544368, 544369, 544370, 549 77, 549 78, 558426, 568327, 568808, A61K 31495, A61K 31505, C07D40306, C07D41306
Patent
active
056437846
ABSTRACT:
The subject invention relates to 5-Substituted trans-1-piperazinoindan derivatives having general formula (I), ##STR1## wherein X is halogen, trifluromethyl, alkyl, alkylthio, alkyloxy, hydroxy, alkylsulphonyl, alkyl- or dialkylamino, triflouromethylthio or cyano; R is hydrogen, or alkyl, alkenyl, cycloalkyl, cycloalkyl lower alkyl, optionally substituted with hydroxy, or R is a substituent, ##STR2## wherein n is an integer from 1 to 6; U is CH or N; Y is, CH.sub.2, O, S or N-R.sup.1, R.sup.1 being hydrogen or cycloalkyl, cycloalkylmethyl, alkyl or alkenyl optionally substituted with hydroxy or an optionally substituted phenyl group; W is O or S; Z is --(CH.sub.2).sub.4 --, ##STR3## where R.sup.2 and R.sup.3 are hydrogen or lower alkyl, --CH.dbd.CH--, --CH.dbd.CH--CH.sub.2 --, optionally substituted 1,2-phenylene, 1,2-C.sub.6 H.sub.4 CH.sub.2 -- (to form a quinazolidinone or -thione ring system) or 1,2-C.sub.6 H.sub.4 CO-- (to form a quinazolidindion or thixoquinazolidinon ring system); and Ar is an optionally substituted phenyl, thiophene or furane ring; are selective, centrally acting 5-HT.sub.2 antagonists useful in the treatment of anxiety, depression, sleeping disorders, negative symptoms of schizophrenia and migraine.
REFERENCES:
patent: 2891066 (1959-06-01), Parcell
patent: 3135794 (1964-06-01), Archer
patent: 3408356 (1968-10-01), Horovitz
patent: 3476760 (1969-11-01), Kaiser et al.
patent: 3558637 (1971-01-01), Kaiser et al.
patent: 3980658 (1976-09-01), Possanza et al.
patent: 3993764 (1976-11-01), Dumont et al.
patent: 3996211 (1976-12-01), Lassen
patent: 4038395 (1977-07-01), Lassen
patent: 4139634 (1979-02-01), Pigerol et al.
patent: 4196209 (1980-04-01), Dumont et al.
patent: 4208417 (1980-06-01), Uzan et al.
patent: 4251538 (1981-02-01), Hausberg et al.
patent: 4333939 (1982-06-01), Guillaume et al.
patent: 4358456 (1982-11-01), Ward
patent: 4443448 (1984-04-01), Bogeso
patent: 4525360 (1985-06-01), Perregaard
patent: 4530932 (1985-07-01), Clemence et al.
patent: 4670447 (1987-06-01), Strupczewski
patent: 4684650 (1987-08-01), Bogeso
patent: 4701462 (1987-10-01), Wyllie
patent: 4710500 (1987-12-01), Perregaard
patent: 4772612 (1988-09-01), Goldmann et al.
patent: 4831031 (1989-05-01), Lowe, III et al.
patent: 4847254 (1989-07-01), Boegesoe et al.
patent: 4853470 (1989-08-01), Strupczewski
patent: 4873344 (1989-10-01), Bogeso et al.
patent: 4946863 (1990-08-01), Boegesoe et al.
patent: 4997841 (1991-03-01), Oxford et al.
patent: 5036078 (1991-07-01), Coates
patent: 5068325 (1991-11-01), Grell et al.
patent: 5112838 (1992-05-01), Perregaard et al.
patent: 5216001 (1993-06-01), Perregaard et al.
Adachi et al. (1985) "Aminohaloborane in Organic Synthesis. IX..sup.1) Exclusive Ortho Acylation Reaction of N-Monoaminoalkylani-lines", Chem. Pharm. Bull., vol.33(5), pp. 1826-1835.
Arnt, J. et al. (1989), "In Vivo Pharmacology of Irindalone, a 5-HT.sub.2 Receptor Atanagonist With Predominant Peripheral Effects", Drug Develop. Res., vol. 16, pp. 59-70.
Bally et al. (1887) Chem. Ber., vol. 20, p. 2590.
B.o slashed.ges.o slashed., K. P. et al. (1993), "Stereospecific and Selective 5-HT.sub.2 Antagonism in a Series of 5-Substituted trans-1-Piperazino-3-Phenylindans", J. Med. Chem., vol. 36, pp. 2761-2770.
B.o slashed.ges.o slashed., K. P. et al. (1985), "3-Phenyl-1-indanamines. Potential Antidepressant Activity and Potent Inhibition of Dopamine, Norepinephrine, and Serotonin Uptake", J. Med. Chem., vol. 28, pp. 1817-1828.
B.o slashed.ges.o slashed., K. P. et al. (1988), "Antihypertensive Activity in a Series of 1-Piperazino-3-phenylindans with Potent 5-HT.sub.2 -Antagonostic Activity", J. Med. Chem., vol. 31, pp. 2247-2256.
B.o slashed.ges.o slashed., K. P. (1983), "Neuroleptic Activity and Dopamine-Uptake Inhibition in 1-Piperazino-3-phenylindans", J. Med. Chem., vol. 26, pp. 935-947.
Casini, G. et al. (1969), "On 1,2-Benzisoxazole-3-acetic Acid and 3-Methyl-1,2-Bennzisoxazole: A Restatement", J. Het. Chem., vol. 6, pp. 279-283.
Gladstone et al. (1965), J. Chem. Soc., vol. 7, 3048.
Greuter et al. (1974), Helv. Chem. Acta, vol. 57, p. 281.
Hino, T. et al. (1974), "Bromination of 3-Phenylindoles", Tetrahedron, vol. 30, pp. 2123-2133.
Hughes, G. K. et al. (1939), "Researchers of Indoles", J. Proc. Roy. Soc. N.S.Wales, vol. 72, pp. 209-221.
Hyttel, J. et al. (1985), "Neurochemical Profile of Lu 19-005, a Potent Inhibitor of Uptake of Dopamine, Noradrenaline, and Serotonin", J. Neurochem, vol. 44, pp. 1615-1622.
Hyttel, J. et al. (1988), "Neurochemical Profile In Vitro of Irindalone: A 5-HT.sub.2 -Receptor Antagonist", Drug. Dev. Res., vol. 15, pp. 389-404.
Jones, C.D. (1972), J. Org. Chem., vol. 37, pp. 3624.
LeFur, G. et al. (1977), "Effects of 4-(3-Indolyl-Alkyl)Piperidine Derivatives on Uptake and Release of Noradrenaline, Dopamine and 5-Hydroxytryptamine in Rat Brain Synaptosomes, Rat Heart and Human Blood Platelets", Biochem. Pharmacol, vol. 26, pp. 497-503.
Martin et al. (1989), "Activity of Aromatic Substituted Phenylpiperazines Lacking Affinity for Dopamine Binding Sites in a Preclinical Test of Antipsyuchotic Efficacy", J. Med. Chem., vol. 32, pp. 1052-1056.
Mays, R. P. et al. (1980), "Synthesis of 2-Amino-3-Benzoylphenylacetic Acid", J. Heterocyclic Chem., vol. 17, No. 8, pp. 1663-1664.
McElvain, S. M. et al. (1950), "Piperidine Derivatives. XXIII. Certain Halogenated 1-Methyl-4-Phenylpiperidines and Related Compounds", J. Amer. Chem. Soc., vol. 72, pp. 3134-3138.
McMillen, B. A. et al. (1988), "N-Alkyl-Substituted Aryl-Piperazine Drugs: Relationship Between Affinity for Serotonin Receptors and Inhibition of Aggression", Drug Develop. Res., vol. 12, pp. 53-62.
Morooka, S. et al. (1978), "A Convenient Synthesis of 2-Cyano-3-Phenylindoles", Synthesis, No. 6, pp. 445 & 446.
Schulenberg, J. W. et al. (1965), "The Chapman Rearrangement", Organic Reactions, vol. 14, pp. 1-51.
Perregaard, J. et al. (1992), "Noncataleptogenic, Centrally Acting Dopamien D-2 and Serotonin 5-HT.sub.2 Antagonists within A Series of 3-Substituted 1-(4-Fluorophenyl)-1H-indoles", J. Med. Chem., vol. 35, pp. 1092-1101.
Rao, T. S. et al. (1990), "Inhibition of Climbing and Mossy Fiber, and Basket and Stellate Cell Inputs to Mouse Cerebellar Purkinje Cells by Novel Anti-Ischemic Agents, Ifenprodil and BMY-14802", Life Sciences, vol. 47, pp. PL-1-PL-5.
Rosenzweig-Lipson, S. et al. (1992), "Stereoselectic Behavioral Effects of Lu 19-005 in Monkeys: Relation to Binding at Cocaine Recognition Sites", Psychopharmacology, vol. 107, pp. 186-194.
Sanchez et al. (1991), "Neurochemical and In Vivo Pharmacological Profile of Sertindole, a Limbic-Selective Neuroleptic Compound", Drug Deve. Res., vol. 22, pp. 239-250.
Skarsfeldt, T. et al. (1990), "Sertindole, A New Neuroleptic with Extreme Selectivity on A10 Versus A9 Dopamine Neurones in the Rat", Eur. J. Pharmacol., vol. 182, pp. 613-614.
Szabo-Pusztay et al. (1979), "A Simple General Method for the Oxidation of Indoles to Oxindoles", Synthesis, vol. 86, pp. 276-277.
Ueda et al., "Preparation of Piperidinoalkyl Thiazoles as Antiallergic Agents", Chemical Abstract, vol. 107, Abstract No. 236692F (1987).
Yamamoto, H. et al. (1968), "I-Acylindoles. VII..sup.1) On Formation Reaction of Indoles from Phenylhydrazines with Several Acidic Catalysts", Chem. Pharm. Bull., vol. 16, No. 12, pp. 2313-2319.
Rao, Tadimeti S. et al. (1990), "BMY-14802 Antagonizes Harmaline-and D-Serine-Induced Increases in Mouse Cerebellar Cyclic GMP: Neurochemical Evidence for a .sigma. Receptor-Mediated Functional Modulation of Responses Mediated by the N-Methyl-D-aspartate Receptor Complex In Vivo", Molecular Pharmacology, vol. 37, pp. 978-982.
Martin, PT et al. (1994), "Efficacy and Safety of Sertindole in Two Double-Blind, Placebo-Controlled Trials of Schizophrenic Patients", Schizophrenia Research, vol. 11, p. 107.
B.o slashed.ges.o slashed. Klaus P.
Bregnedal Peter
Bernhardt Emily
H, Lundbeck A/S
LandOfFree
Indan derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indan derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indan derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-596192